Product Information
DOXYCYCLINE MONO 150 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $0.6337 per EA under NDC 64380020801. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Dec 15, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380020801
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXYCYCLINEApproval Type
Generic (ANDA)
FDA Application
ANDA065070FDA Approved
12/15/2000
TE Code
AB
On Market Since
9/19/2022
Pharmacological Classes
Price Statistics
The NADAC for DOXYCYCLINE MONO 150 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 43.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6337 per EA |
|---|---|
| All-time high | $1.2023 (May 14, 2025) |
| All-time low | $0.6337 (Sep 23, 2026) |
| 52-week high | $1.0039 |
| 52-week low | $0.6337 |
| Median price | $0.9453 |
| Average price | $0.9122 |
| Largest weekly change | -19.0% (May 21, 2025) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the doxycycline market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
doxycycline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tetracycline-class Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXYCYCLINE MONO 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DOXYCYCLINE MONO 150 MG TABLET, manufactured by Strides Pharma Inc., is $0.6337 per EA (NDC 64380020801), effective Sep 30, 2026.
How has the price of DOXYCYCLINE MONO 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for DOXYCYCLINE MONO 150 MG TABLET has declined 43.7%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DOXYCYCLINE MONO 150 MG TABLET?
Since Apr 17, 2024, the NADAC for DOXYCYCLINE MONO 150 MG TABLET has ranged from a low of $0.6337 (Sep 23, 2026) to a high of $1.2023 (May 14, 2025), with a median of $0.9453 per EA.
Are there cheaper alternatives to DOXYCYCLINE MONO 150 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of DOXYCYCLINE MONO 150 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXYCYCLINE MONO 150 MG TABLET?
DOXYCYCLINE MONO 150 MG TABLET (NDC 64380020801) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.